The role of telomerase reverse transcriptase (TERT) in human malignancies : genetic regulation and telomere lengthening-independent oncogenic activities
Author: Yu, Jingya
Date: 2018-06-01
Location: CMM lecture hall L8:00, Karolinska University Hospital, Solna
Time: 09.00
Department: Inst för medicin, Solna / Dept of Medicine, Solna
View/ Open:
Thesis (1.361Mb)
Abstract
Telomerase is a ribonucleoprotein enzyme maintaining telomere length. Telomerase reverse transcriptase (TERT), which acts as a catalytic unit, is tightly repressed in differentiated human cells while activated in cancer cells for telomere lengthening. Beyond that, TERT has also been shown to contribute to oncogenesis via its telomere lengthening-independent functions. This thesis is designed to define the role of TERT in oncogenesis and the biological implications of the genetic alterations in the TERT gene/promoter.
The first paper was focused on the role of TERT in acute myeloid leukemia (AML) therapy targeting mutations of FMS-like tyrosine kinases 3 (FLT3). The internal tandem duplication (ITD) mutation in the juxtamembrane domain in the FLT3 gene has been reported as one of the most frequent mutations in AML, and PKC412 was developed as its specific inhibitor. We observed that in FLT3ITD-harboring primary cells from AML patients and AML cell lines, PKC412 down-regulated TERT expression and telomerase activity in a MYC-dependent manner. Moreover, TERT restored the activity of FLT3 downstream effectors and alternative tyrosine kinase signaling pathways inhibited by PKC412, thereby attenuating PKC412-mediated apoptosis of leukemic cells. Taken together, FLT3ITD regulates TERT expression via a MYC-dependent manner, and TERT down-regulation is required for PKC412-mediated anti-AML efficacy.
The recurrent TERT promoter mutations have been demonstrated to stimulate TERT transcription by generating new E26 transformation-specific specific (ETS)-binding sites in different human malignancies. Furthermore, rs2736098 and rs2736100, the two single nucleotide polymorphisms (SNPs) in the TERT locus, have been reported to associate with cancer susceptibility. In paper II, we found that compared to hepatocellular carcinoma (HCC) patients with wild type TERT promoter or healthy controls, a significant difference in these two genotypes was present in patients carrying TERT promoter mutations. We observed a negative association between TERT promoter mutations and rs2736098_TT and rs2736100_CC genotypes. There was no association between TERT promoter mutations and clinico-pathological variables or CTNNB1 mutations. In summary, the germline TERT rs2736098 and rs2736100 polymorphisms may play a role in TERT promoter mutation occurrence in HCC.
The dysregulation of DNA methyltransferases (DNMTs) and the aberrant DNA methylation is a cancer hallmark. In paper III, we showed that TERT up-regulated DNA methyltransferase 3B (DNMT3B) expression and thereby contributing to the repression of downstream tumor suppressors as well as the activation of AKT. We found a positive correlation between TERT and DNMT3B expression in both HCC cell lines and primary HCC tumors. Mechanistically, TERT promotes DNMT3B transcription by cooperating with the transcription factor (TF) Sp1. The depletion of TERT expression led to significant demethylation in the tumor suppressor PTEN promoter and a reduced global DNA methylation by down-regulating DNMT3B expression. The restoration of PTEN expression mediated by TERT depletion inhibited AKT activity. Higher levels of TERT and DNMT3B expression predicted a significantly shorter survival in HCC patients according to analysis of The Cancer Genome Atlas (TCGA) dataset. Taken together, we identified the TERT-DNMT3B-PTEN-AKT axis in
HCC cells, which promotes HCC progression via aberrant DNA methylation.
In conclusion, our studies demonstrated the effect of genetic alterations on TERT/telomerase activation, and the novel telomere lengthening-independent roles of TERT in carcinogenesis, which should be implicated in cancer therapy/precision oncology.
The first paper was focused on the role of TERT in acute myeloid leukemia (AML) therapy targeting mutations of FMS-like tyrosine kinases 3 (FLT3). The internal tandem duplication (ITD) mutation in the juxtamembrane domain in the FLT3 gene has been reported as one of the most frequent mutations in AML, and PKC412 was developed as its specific inhibitor. We observed that in FLT3ITD-harboring primary cells from AML patients and AML cell lines, PKC412 down-regulated TERT expression and telomerase activity in a MYC-dependent manner. Moreover, TERT restored the activity of FLT3 downstream effectors and alternative tyrosine kinase signaling pathways inhibited by PKC412, thereby attenuating PKC412-mediated apoptosis of leukemic cells. Taken together, FLT3ITD regulates TERT expression via a MYC-dependent manner, and TERT down-regulation is required for PKC412-mediated anti-AML efficacy.
The recurrent TERT promoter mutations have been demonstrated to stimulate TERT transcription by generating new E26 transformation-specific specific (ETS)-binding sites in different human malignancies. Furthermore, rs2736098 and rs2736100, the two single nucleotide polymorphisms (SNPs) in the TERT locus, have been reported to associate with cancer susceptibility. In paper II, we found that compared to hepatocellular carcinoma (HCC) patients with wild type TERT promoter or healthy controls, a significant difference in these two genotypes was present in patients carrying TERT promoter mutations. We observed a negative association between TERT promoter mutations and rs2736098_TT and rs2736100_CC genotypes. There was no association between TERT promoter mutations and clinico-pathological variables or CTNNB1 mutations. In summary, the germline TERT rs2736098 and rs2736100 polymorphisms may play a role in TERT promoter mutation occurrence in HCC.
The dysregulation of DNA methyltransferases (DNMTs) and the aberrant DNA methylation is a cancer hallmark. In paper III, we showed that TERT up-regulated DNA methyltransferase 3B (DNMT3B) expression and thereby contributing to the repression of downstream tumor suppressors as well as the activation of AKT. We found a positive correlation between TERT and DNMT3B expression in both HCC cell lines and primary HCC tumors. Mechanistically, TERT promotes DNMT3B transcription by cooperating with the transcription factor (TF) Sp1. The depletion of TERT expression led to significant demethylation in the tumor suppressor PTEN promoter and a reduced global DNA methylation by down-regulating DNMT3B expression. The restoration of PTEN expression mediated by TERT depletion inhibited AKT activity. Higher levels of TERT and DNMT3B expression predicted a significantly shorter survival in HCC patients according to analysis of The Cancer Genome Atlas (TCGA) dataset. Taken together, we identified the TERT-DNMT3B-PTEN-AKT axis in
HCC cells, which promotes HCC progression via aberrant DNA methylation.
In conclusion, our studies demonstrated the effect of genetic alterations on TERT/telomerase activation, and the novel telomere lengthening-independent roles of TERT in carcinogenesis, which should be implicated in cancer therapy/precision oncology.
List of papers:
I. Xiaolu Zhang, Bingnan Li, Jingya Yu, Jenny Dahlström, Anh Nhi Tran, Magnus Björkholm, Dawei Xu. MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia. Annals of Hematology. 2018;97(1):63-72.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Xiaotian Yuan, Guanghui Cheng, Jingya Yu, Shunzhen Zheng, Chao Sun, Qing Sun, Kailin Li, Zhaomin Lin, Tiantian Liu, Ping Li, Yiteng Xu, Feng Kong, Magnus Björkholm M, Dawei Xu. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma. Oncotarget. 2017;8(14):23120-23129.
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Jingya Yu, Xiaotian Yuan, Louise Sjöholm, Tiantian Liu, Feng Kong, Tomas J. Ekström, Magnus Björkholm, Dawei XU. Telomerase reverse transcriptase is required for DNMT3B expression/ aberrant DNA methylation phenotype and AKT activation in hepatocellular carcinoma. [Submitted]
I. Xiaolu Zhang, Bingnan Li, Jingya Yu, Jenny Dahlström, Anh Nhi Tran, Magnus Björkholm, Dawei Xu. MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia. Annals of Hematology. 2018;97(1):63-72.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Xiaotian Yuan, Guanghui Cheng, Jingya Yu, Shunzhen Zheng, Chao Sun, Qing Sun, Kailin Li, Zhaomin Lin, Tiantian Liu, Ping Li, Yiteng Xu, Feng Kong, Magnus Björkholm M, Dawei Xu. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma. Oncotarget. 2017;8(14):23120-23129.
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Jingya Yu, Xiaotian Yuan, Louise Sjöholm, Tiantian Liu, Feng Kong, Tomas J. Ekström, Magnus Björkholm, Dawei XU. Telomerase reverse transcriptase is required for DNMT3B expression/ aberrant DNA methylation phenotype and AKT activation in hepatocellular carcinoma. [Submitted]
Institution: Karolinska Institutet
Supervisor: Xu, Dawei
Co-supervisor: Björkholm, Magnus; Yuan, Xiaotian
Issue date: 2018-05-09
Rights:
Publication year: 2018
ISBN: 978-91-7831-042-5
Statistics
Total Visits
Views | |
---|---|
The ... | 328 |
The ...(legacy) | 307 |
Total Visits Per Month
September 2023 | October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | |
---|---|---|---|---|---|---|---|
The ... | 1 | 2 | 1 | 0 | 2 | 0 | 0 |
File Visits
Views | |
---|---|
Thesis_Jingya_Yu.pdf | 746 |
Thesis_Jingya_Yu.pdf(legacy) | 123 |
null(legacy) | 1 |
Top country views
Views | |
---|---|
Sweden | 147 |
United States | 134 |
China | 51 |
Germany | 39 |
India | 18 |
South Korea | 12 |
Canada | 11 |
Japan | 10 |
Egypt | 8 |
United Kingdom | 8 |
Top cities views
Views | |
---|---|
Ashburn | 51 |
Beijing | 16 |
Lane | 16 |
Stockholm | 11 |
Seoul | 9 |
Dublin | 8 |
Woodbridge | 7 |
Chicago | 6 |
Delta | 6 |
Mountain View | 5 |